• Sun, April 27, 2025
  • Mon, April 28, 2025
  • Tue, April 29, 2025
  • Wed, April 30, 2025
  • Thu, May 1, 2025

Merck KGaA in late-stage talks to acquire SpringWorks for USD 3.5 billion

Bengaluru: Merck KGaA, a science and technology company, is in late-stage negotiations to buy SpringWorks Therapeutics, a US based commercial-stage biopharmaceutical company for approximately $3.5...
Merck KGaA, a German science and technology company, is reportedly in advanced discussions to acquire SpringWorks Therapeutics, a U.S.-based biopharmaceutical company, for approximately $3.5 billion. The potential acquisition aims to bolster Merck's oncology portfolio, as SpringWorks focuses on developing treatments for severe rare diseases and cancer. The deal, if finalized, would represent a significant expansion of Merck's capabilities in the biopharmaceutical sector, particularly in the area of targeted cancer therapies.

Read the Full Daily Article at:
https://medicaldialogues.in/news/industry/pharma/merck-kgaa-in-late-stage-talks-to-acquire-springworks-for-usd-35-billion-147337